Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Mirikizumab · Omvoh, LY-3074828

Monoclonal antibody · Antagonist of interleukin-23 subunit alpha (IL-23 p19) (IL23A) · developed by Eli Lilly And Co

Approved FDA, Oct 2023

LLY Developer

2 Registered trials

What is Mirikizumab?

Mirikizumab is a humanized IgG4 monoclonal antibody that selectively binds the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor, reducing pro-inflammatory cytokine and chemokine release.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Omvoh, LY-3074828
Drug type: Monoclonal antibody
Targets: interleukin-23 subunit alpha (IL-23 p19) (IL23A)
Mechanism: Antagonist of interleukin-23 subunit alpha (IL-23 p19) (IL23A)
Pathways: IL-23 signaling, pro-inflammatory cytokine and chemokine release
Therapy area: Gastroenterology
Developer: Eli Lilly And Co (LLY)
FDA status: Approved as Omvoh (October 26, 2023), BLA761279 · FDA label
UNII: Z7HVY03PHP

✅ FDA-approved uses

Ulcerative colitis
Crohn's disease

From the indications section of the FDA label (version of Jun 16, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07483099	Phase 2	Crohn Disease	Recruiting	LLY
NCT07186101	Phase 2	Ulcerative Colitis	Recruiting	LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Crohn DiseaseUlcerative Colitis

More from Eli Lilly And Co

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3 Clazakizumab Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Mirikizumab

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z